Blog

Alte afecțiuni de sănătate

Stelara (Ustekinumab)

Monoclonal antibody Stelara

Stelara (ustekinumab) is a prescription-only drug that falls under the following drug classes: monoclonal antibodies, antipsoriatics, and interleukin inhibitors. It is given by intravenous (IV) or subcutaneous (SC) injection. Stelara can be used alone or with other medications, depending on the patient’s condition and disease.

Discutați cu un specialist despre asistența pentru coplată

(877) 778-0318

Patients may self-administer Stelara after proper training from a healthcare professional and with physician approval.

Before using this medicine, inform your doctor or pharmacist if:

  • You are allergic to Stelara.
  • You had any other previous drug or food allergies.
  • You have a prior history of infection, such as tuberculosis, cancer, or hepatitis.
  • You are pregnant or planning to become pregnant.
  • You are breastfeeding.
  • You are using any non-prescription, prescription, or herbal drugs.

What Is Stelara?

Stelara is a monoclonal antibody medication, also known by its generic name ustekinumab. It is used to treat various diseases, such as psoriatic arthritis, Boala Crohn, plaque psoriasis, and ulcerative colitis.

What Is Stelara Used To Treat? 

Stelara is a prescription-based medication used to treat the following:

  • A specific type of arthritis, such as psoriatic arthritis. Psoriatic arthritis is the swelling and stiffness of the affected joints and is painful.
  • Plaque psoriasis, characterized by red, flaky, and raised skin, which is painful, itchy, and cracky. It develops anywhere on the skin surface, like the elbows, arms, knees, trunk, or scalp.
  • Certain bowel disorders, such as Crohn’s disease and ulcerative colitis. Ulcerative colitis is the inflammation of the large intestine, commonly the rectum, and Crohn’s disease is the swelling and inflammation of the digestive tract.

How Does Stelara Works? Mechanism of Action

Ustekinumab is a human monoclonal antibody that binds to and interferes with the proinflammatory cytokines, interleukin-12 (IL-12) and interleukin-23 (IL-23). Ustekinumab also interferes with the expression of monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), interferon-inducible protein-10 (IP-10), and interleukin-8 (IL-8).

In most of the inflammatory diseases, such as Crohn’s disease, the levels of inflammatory cytokine and other interleukins are elevated. Stelara works by inhibiting cytokines and blocking the action of IL-23 and IL-12. This reduces inflammation and treats the disease symptoms.

How Is Stelara Used?

  • Stelara can be used intravenously or subcutaneously, depending on the doctor’s recommendation and the patient’s condition. 
  • It can be used alone or in combination with another medicine, like methotrexate (in diseases like psoriatic arthritis).
  • Stelara should not be used in children under 6 years of age.
  • Stelara can be taken with or without food.

Vorbește cu un specialist

Programați o consultație

Side Effects of Stelara 

The common side effects of Stelara go away as the body gets used to the drug. But if they become persistent, severe, or intolerable, consult your doctor.

Stelara side effects

The common side effects of Stelara include:

  • Greață și vărsături
  • Diaree
  • Febră
  • Durere de stomac
  • Durere de cap
  • Disconfort în piept
  • Pain or burning while urinating
  • Mâncărime

The severe side effects of Stelara include:

  • Swelling, pain, redness, and warmth anywhere on the body
  • Worsening cough
  • Convulsii
  • Sudden chest pain
  • Durere de cap severă
  • Change in mental status
  • Sudden and severe stomach pain
  • Vision problems
  • Confuzie 
  • Dificultăți de respirație 

Warnings/Precautions

Stelara may increase the risk for infections or reactivation of latent infections, such as tuberculosis. Common infections include upper respiratory infections, urinary tract infections, sinus infections, bronchitis, and vaginal yeast infections. Avoid use in patients with clinically important active infection until the infection resolves or is successfully treated.

Rezistenţă

Stelara is available in the following strengths:

  • 45 mg injection
  • 90 mg injection 
  • 130 mg/26 ml for intravenous infusion

The initial dose is given at week 0, then after 4 weeks, followed by every 12 weeks.

Dozare

The dose of Stelara varies depending on the patient’s weight and the disease for which they are taking the drug.

The adult dose of Stelara for the following diseases are given below:

Dose for Psoriasis:

  • The recommended subcutaneous dose for patients weighing 100 kg or less is initially 45 mg, followed by 45 mg 4 weeks later, and then 45 mg every 12 weeks.
  • For patients weighing above 100 kg, the subcutaneous dose is initially 90 mg, followed by 90 mg 4 weeks later, and then 90 mg every 12 weeks.

Dose for Crohn’s Disease and Ulcerative Colitis: 

  • The recommended intravenous infusion adult dose of Stelara for patients weighing 55 kg or less is 260 mg.
  • For patients weighing 55 – 85 kg, the IV infusion dose of Stelara is 390 mg.
  • For patients weighing above 85 kg, the IV infusion dose is 520 mg.

After the induction dose above, a maintenance dose of 90 mg should be given every 8 weeks. 

Dose for Psoriatic Arthritis:

  • The recommended subcutaneous dose for patients weighing 100 kg or less is initially 45 mg, followed by 45 mg 4 weeks later, and then 45 mg every 12 weeks.
  • For patients weighing above 100 kg and with moderate to severe psoriatic arthritis, the subcutaneous dose is initially 90 mg, followed by 90 mg 4 weeks later, and then 90 mg every 12 weeks.

Obțineți asistență pentru coplată

Asistență financiară
(877) 778-0318

Stelara Storage And Administration Instructions

  • Store intact vials and prefilled syringes at 2°C to 8°C (36°F to 46°F); do not freeze.
  • If needed, store the diluted solution at room temperature (below 30°C/86°F) for 30 days or less in the original carton to protect it from light. Once stored at room temperature, the syringe should not be returned to the refrigerator and should be discarded if not used within 30 days.  
  • After administration, if any portion of the infusion remains unused, discard the solution.
  • The injection site should be closely monitored for any signs of bleeding, bruising, or swelling.
  • It is recommended that the injection site should be changed each time the drug is administered. Possible injection sites include the thighs, gluteal region, upper arms, or abdomen.

Preţ 

The price of Stelara depends on various factors. For example, your pharmacy and its location, your prescribed treatment regimen, and your insurance plan can all play a role in influencing the price you pay.

The average cost of a Stelara subcutaneous injection is around $13,434 for 0.5 ml.

Întrebări frecvente

What kind of drug is Stelara?

Stelara is a type of drug known as a biologic. It is approved for the treatment of psoriasis, arthritis, and Crohn’s disease.

Is Stelara a steroid?

No. Stelara is not a steroid; it is an immunomodulator and an interleukin inhibitor that works to inhibit cytokines and block the action of IL-23 and IL-12.

How quickly does Stelara work?

On average, Stelara starts to show its effect within 3 to 6 weeks. However, the response time can vary from patient to patient. The majority of patients stayed in remission 1 year after responding to the initial dose and continuing treatment with Stelara.

Concluzie 

Stelara, known by its generic name ustekinumab, is a prescription-based drug used to treat some types of ulcers, arthritis, and inflammatory gastrointestinal diseases. It is available both subcutaneously and intravenously. 

Stelara works by inhibiting inflammatory proteins in our body, such as cytokines and interleukins, hence treating inflammation and its symptoms. The drug should be used cautiously in pregnancy and breastfeeding.

Aceste informații nu înlocuiesc sfatul sau tratamentul medical. Discutați cu medicul dumneavoastră sau cu furnizorul de servicii medicale despre afecțiunea dumneavoastră medicală înainte de a începe orice tratament nou. AmeriPharma® Specialty Care nu își asumă nicio răspundere pentru informațiile furnizate sau pentru orice diagnostic sau tratament efectuat ca urmare a acestuia și nici nu este responsabil pentru fiabilitatea conținutului. AmeriPharma® Specialty Care nu operează toate site-urile web/organizațiile enumerate aici și nici nu este responsabil pentru disponibilitatea sau fiabilitatea conținutului acestora. Aceste listări nu implică și nu constituie o aprobare, sponsorizare sau recomandare din partea AmeriPharma® Specialty Care. Această pagină web poate conține referințe la medicamente eliberate pe bază de rețetă, care sunt mărci comerciale sau mărci comerciale înregistrate ale producătorilor farmaceutici care nu sunt afiliați cu AmeriPharma® Specialty Care.
Dr. Abdelaziz Alsamarah
REVIZUIT MEDICAL DE Dr. Abdelaziz Alsamarah, medic specialist în farmacii, MSPS, BCSCP

Dr. Alsamarah a obținut diploma de doctor în farmacie de la Universitatea din Iordania în 2011. În căutarea unor studii superioare, s-a alăturat Universității Western de Științe ale Sănătății din Pomona, California, în 2014 și a obținut un master în științe farmaceutice, cu specializare în Proiectare Asistată de Calculator a Medicamentelor (CADD). Este autor și coautor al mai multor publicații în reviste științifice importante. După absolvire, Dr. Alsamarah a lucrat în diverse medii farmaceutice înainte de a-și descoperi pasiunea pentru gestionarea pacienților cu perfuzii intravenoase. Domeniile sale de specializare includ: boli infecțioase, suport nutrițional și anticorpi monoclonali. În timpul liber, îi place boxul, ciclismul și pictura alături de cei trei copii ai săi.

Contactaţi-ne

Folosiți formularul conform HIPAA de mai jos pentru a solicita o reînnoire a rețetei dumneavoastră. Dacă aveți întrebări despre medicamentul dumneavoastră sau despre cum să îl administrați, vă rugăm să vizitați pagina Contactați-ne sau să ne sunați la (877) 778-0318.

HIPAA Compliant

Prin trimitere, sunteți de acord cu AmeriPharma Termeni de utilizare, Politica de confidențialitateși Notificare privind practicile de confidențialitate

ro_RORomanian